ArticlePacing and clinical electrophysiology : PACE2026
Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis.
Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown.
methodsA retrospective analysis was conducted using the National Inpatient Sample 2017-2020 with respective ICD-10 codes. Weighted multivariate regression was used to analyze in-hospital mortality by adjusting for confounders.
resultsAmong 1,008,010 patients hospitalized for CDI, 160 patients had underlying AL-AMD, while 200 patients had underlying ATTR-AMD. Patients undergoing CDI with underlying ATTR-AMD had a higher mean age (76.7 vs. 68.4 years, p = 0.001), and a higher male proportion (80% vs. 46.8%, p = 0.005) as compared to those with AL-AMD. ATTR-AMD had a higher CDI rate than AL-AMD (1.4% vs. 8.3%). The predominant device implanted in both AL-AMD and ATTR-AMD was a permanent pacemaker (PPM) (0.8% vs. 5.7%). Underlying AL-AMD was associated with higher in-hospital mortality in patients undergoing PPM (OR 5.1, CI 1.3-19, p = 0.01), and implantable-cardioverter defibrillator (ICD) implantation (OR 21.5, CI 4.6-99, p < 0.001). Patients undergoing CDI with underlying AL-AMD had a higher mean length of stay.
conclusionATTR-AMD has a higher CDI rate as compared to AL-AMD. Underlying AL-AMD is associated with higher in-hospital mortality in patients undergoing PP and ICD implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.